Fulgent will use its Parkinson's disease NGS panel to target seven genes linked to the condition and generate curated reports for doctors and researchers.
23andMe customers who have one of three common variants identified in reports can choose six family members to receive health and ancestry test kits.
Israel-based software company Medial EarlySign will work with Geisinger's innovation center to develop technologies to predict lower GI and other "high-burden" diseases.
Five hundred pharmacies will provide information about pharmacogenetic testing to members who have failed one or more antidepressant treatments.
Inspirata said that the entity will assist hospitals and universities across Europe with data processing, including inter-institutional processing.
The partners are working together to advance tests that will identify which cancer patients have Notch activating mutations and fusions.
The new partnership also gives clinical Dx analytics firm Prognos access to Datavant's pharma and biotech customers.
AnchorDx, based in Guangzhou in southern China, will use Illumina's MiSeqDx sequencer to develop IVD cancer test kits and data analysis software.
AmoyDx and Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development.
Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.